Martin Gutierrez

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Combination Therapy

Intellectual Disability

Top Venues

Cancer research

Nature medicine

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Patricia J Keller, Elizabeth J Adams, Rentian Wu, Alexandre Côté, Shilpi Arora, Nico Cantone, Rosana Meyer, Jennifer A Mertz, Victor Gehling, Jike Cui, Jacob I Stuckey, Avinash Khanna, Feng Zhao, Zehua Chen, Ziyang Yu, Richard T Cummings, Mohammed Taimi, Nehal J Lakhani, Drew W Rasco, Martin Gutierrez, Linda R Duska, Michael Devitt, Ronda Rippley, Julian R Levell, Jennifer Truong, Jing Wang, Kaiming Sun, Patrick Trojer
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Cancer research 84 (15) (2024)
Patricia J Keller, Elizabeth J Adams, Rentian Wu, Alexandre Côté, Shilpi Arora, Nico Cantone, Rosana Meyer, Jennifer A Mertz, Victor Gehling, Jike Cui, Jacob I Stuckey, Avinash Khanna, Feng Zhao, Zehua Chen, Ziyang Yu, Richard T Cummings, Mohammed Taimi, Nehal J Lakhani, Drew W Rasco, Martin Gutierrez, Linda R Duska, Michael Devitt, Ronda Rippley, Julian R Levell, Jennifer Truong, Jing Wang, Kaiming Sun, Patrick Trojer
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Cancer research 84 (15) (2024)
Patricia J Keller, Elizabeth J Adams, Rentian Wu, Alexandre Côté, Shilpi Arora, Nico Cantone, Rosana Meyer, Jennifer A Mertz, Victor Gehling, Jike Cui, Jacob I Stuckey, Avinash Khanna, Feng Zhao, Zehua Chen, Ziyang Yu, Richard T Cummings, Mohammed Taimi, Nehal J Lakhani, Drew W Rasco, Martin Gutierrez, Linda R Duska, Michael Devitt, Ronda Rippley, Julian R Levell, Jennifer Truong, Jing Wang, Kaiming Sun, Patrick Trojer
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Cancer research (2024)
Justin F Gainor, Manish R Patel, Jeffrey S Weber, Martin Gutierrez, Julie E Bauman, Jeffrey M Clarke, Ricklie Julian, Aaron James Scott, Jessica L Geiger, Kedar S Kirtane, Celine Robert-Tissot, Brandon Coder, Moomal Tasneem, Jing Sun, Wei Zheng, Lauren Gerbereux, Andressa Laino, Filippos Porichis, Jack Pollard, Peijie Hou, Vasudha Sehgal, Xing Chen, Manju Morrissey, Hikmat N Daghestani, Igor Feldman, Lakshmi Srinivasan, Joshua P Frederick, Michelle Brown, Praveen Aanur, Robert Meehan, Howard A Burris
T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study. Cancer discovery (2024)
Patricia J Keller, Elizabeth J Adams, Rentian Wu, Alexandre Côté, Shilpi Arora, Nico Cantone, Rosana Meyer, Jennifer A Mertz, Victor Gehling, Jike Cui, Jacob I Stuckey, Avinash Khanna, Feng Zhao, Zehua Chen, Ziyang Yu, Richard T Cummings, Mohammed Taimi, Nehal J Lakhani, Drew W Rasco, Martin Gutierrez, Linda R Duska, Michael Devitt, Ronda Rippley, Julian R Levell, Jennifer Truong, Jing Wang, Kaiming Sun, Patrick Trojer
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers. Cancer research 84 (15) (2024)
Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, Matthew A Gubens, Charu Aggarwal, Daniel Shao-Weng Tan, Enriqueta Felip, Joanne Wing Yan Chiu, Jong-Seok Lee, James Chih-Hsin Yang, Edward B Garon, Giovanna Finocchiaro, Myung-Ju Ahn, Alexander Luft, Gregory A Landers, Andrea Basso, Hua Ma, Julie Kobie, John Palcza, Razvan Cristescu, Lawrence Fong, Alexandra Snyder, Jianda Yuan, Roy S Herbst
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. Nature medicine (2023)
David S Hong, Michael A Postow, Bartosz Chmielowski, Ryan J Sullivan, Amita Patnaik, Ezra E W Cohen, Geoffrey I Shapiro, Conor E Steuer, Martin Gutierrez, Heather Yeckes-Rodin, Robert Ilaria, Brenda C O'Connell, Joanna Peng, Guangbin Peng, Nora Zizlsperger, Anthony W Tolcher, Jedd D Wolchok
Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)